Author

John Brognard

National Institutes of HealthORCID 0000-0002-9243-6615Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

John Brognard1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Carolyn C. WoodroofeiD· 2 shared Eric LindbergiD· 2 shared Maxine R. RubiniD· 2 shared Meghri KaterjiiD· 2 shared Rolf E. SwensoniD· 2 shared Amy E. JamesiD· 1 shared Amy Funk· 1 shared Amy L. FunkiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Carolyn C. WoodroofeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers

Meghri Katerji, Kailey N. Jackett, Maxine R. Rubin, Eric Lindberg, Carolyn C. Woodroofe, Xiaoyi Li, Knickole Bergman, Zoe Weaver Ohler, Stephanie Jorgensen, Xiaohu Zhang, David O. Holland, Mahfuza Sharmin, Amy Funk, Katerine Nyswaner, Noelle Tesi, , John Brognard

This study identifies compound #63 as a potent LZK inhibitor that suppresses tumor growth and enhances EGFR and PI3K pathway blockade in HNSCC and ESCC.

bioRxiv · Oct 20, 2026 · PreprintCancer Biology

Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth

Amy L. Funk, Meghri Katerji, Marwa M. Afifi, Katherine M. Nyswaner, Carolyn C. Woodroofe, Zoe C. Edwards, Eric Lindberg, Knickole L. Bergman, Nancy R. Gough, Maxine R. Rubin, Kamila Karpińska, Eleanor W. Trotter, Sweta Dash, Amy L. Ries, Amy E. James, , John Brognard

This study identifies LZK as a therapeutic target in HNSCC by showing its regulation of c-MYC and GOF p53, and demonstrates PROTAC-mediated degradation as a potential treatment.

Science Signaling · Feb 11, 2025Peer-reviewedCancer Biology